课题基金 / 基金详情

Long-term effects of early-life antipsychotic drug treatment

Long-term effects of early-life antipsychotic drug treatment
生命早期抗精神病药物治疗的长期影响
批准号:
8179930
负责人:
MARK Edward BARDGETT
金额:
$40.62万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-06-01 至 2015-05-31

项目摘要

项目成果

MARK Edward BARDGETT的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):此申请表代表提交R15奖项的申请。这些奖项旨在支持涉及NIH资金有限的机构的本科生的研究。这项研究的目的是开始定义早期接触抗精神病药物(APDS)的长期行为影响。在过去的15年里,儿科人群中使用APDS的人数翻了一番--这一现象在科学界和国家媒体中引起了相当大的关注。这种增加是在相对缺乏基础研究的情况下发生的,这些研究记录了早期接触雪崩对后期大脑和行为功能的影响。对实验室大鼠的动作电位反应的研究将是填补这一空白的重要的第一步。在成年大鼠中,已有充分的证据表明,长期的apd治疗引起的持续受体阻断会导致脑多巴胺功能的代偿性但短暂的变化。相比之下,目前还没有大量的研究可以确定雪崩对发育中的大鼠的长期影响。我们的假设是,由于这种治疗的时机,早期接触APDS可能会导致脑多巴胺功能的代偿性但永久性的变化,这种变化将持续到成年。我们自己的初步研究表明,从出生后14-42天开始,每天服用非典型apd利培酮的大鼠表现出感觉运动门控缺陷和年轻时持续的运动多动--这些行为与前脑多巴胺功能有关。在这些数据和我们的假设的指导下,目前的应用将确定早期利培酮对成年期间运动活动和感觉运动门控的影响是否存在关键时期,以及早期利培酮是否会增加这些行为对多巴胺激动剂的敏感性,增强冲动性,并扰乱成年后前脑多巴胺的释放。这项拟议的工作将作为申请者建立一个研究计划的基础,该计划旨在阐明早期apd治疗的影响。反过来,这将为研究人员、政策制定者和实践者提供关键信息,说明在发育过程中长期接受apd治疗的长期后果。最后,建议的研究将被用作一种媒介,使本科生在精神药理学、发育神经科学和神经化学方面获得独特的和综合的研究体验。 公共卫生相关性:在过去的15年里,儿科人群中抗精神病药物的使用量翻了一番,尽管相对缺乏记录此类药物暴露对后来的大脑和行为功能影响的基础研究。这项研究的目的是确定早期接触抗精神病药物对实验大鼠的长期行为影响。这项研究将为研究人员、政策制定者和实践者提供有关在开发过程中长期接受抗精神病药物治疗的关键信息,此外还将加强北肯塔基大学本科生在神经科学方面的研究经验。
英文摘要
DESCRIPTION (provided by applicant): This application represents a submission for an AREA R15 award. These awards are intended to support research that involves undergraduates at institutions that have limited NIH funding. The purpose of this research is to begin defining the long-term behavioral effects of early-life exposure to antipsychotic drugs (APDs). Over the past 15 years, the use of APDs in pediatric populations has doubled - a phenomenon that has garnered considerable attention in the scientific community and national media. This increase has occurred in the relative absence of basic research documenting the effects of early-life APD exposure on later brain and behavioral function. Studies of APD action in laboratory rats would serve as a significant first step in filling this void. It has been well established in adult rats that continuous receptor blockade caused by long-term APD treatment leads to compensatory yet transient changes in brain dopamine function. In contrast, there is currently no body of research that has ascertained the long-term effects of APD treatment in developing rats. Our hypothesis is that, due to the timing of such treatment, early-life exposure to APDs may engender compensatory yet permanent changes in brain dopamine function that persist through adulthood. Our own preliminary research has shown that rats treated daily with the atypical APD, risperidone, from postnatal days 14 - 42 exhibit sensorimotor gating deficits and persistent locomotor hyperactivity as young adults - behaviors linked to forebrain dopamine function. Guided by these data and our hypothesis, the current application will determine if there are critical periods for the effects of early-life risperidone exposure on locomotor activity and sensorimotor gating during adulthood, and whether early-life risperidone heightens the sensitivity of these behaviors to dopamine agonists, enhances impulsivity, and disrupts forebrain dopamine release in adulthood. The proposed work would act as a foundation for the applicant to establish a program of research aimed at elucidating the effects of early-life APD treatment. In turn, this would provide researchers, policy-makers, and practitioners with critical information regarding the long-term consequences of prolonged APD treatment during development. Finally, the proposed research will be used as a vehicle to engage undergraduates in unique and integrative research experiences in psychopharmacology, developmental neuroscience, and neurochemistry. PUBLIC HEALTH RELEVANCE: The use of antipsychotic drugs in pediatric populations has doubled over the past 15 years despite the relative absence of basic research documenting the effects of such drug exposure on later brain and behavioral function. The purpose of this research is to ascertain the long-term behavioral effects of early-life exposure to antipsychotic drugs in laboratory rats. This research will provide researchers, policy-makers, and practitioners with critical information regarding the long-term consequences of prolonged antipsychotic drug treatment during development, in addition to enhancing research experiences in neuroscience among college undergraduates at Northern Kentucky University.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Brain Development after Early-Life Antipsychotic Treatment
  • 批准号:
    10629613
  • 项目类别:
  • 资助金额:
    $13.7万
  • 财政年份:
    2023
  • 负责人:
    MARK Edward BARDGETT
  • 依托单位:
BARDGETT POST-DOC/TECHNICIAN SUPPORT
  • 批准号:
    8360102
  • 项目类别:
  • 资助金额:
    $6.39万
  • 财政年份:
    2011
  • 负责人:
    MARK Edward BARDGETT
  • 依托单位:
NKU LEAD FACULTY
  • 批准号:
    8360106
  • 项目类别:
  • 资助金额:
    $5.74万
  • 财政年份:
    2011
  • 负责人:
    MARK Edward BARDGETT
  • 依托单位:
BARDGETT POST-DOC/TECHNICIAN SUPPORT
  • 批准号:
    8168278
  • 项目类别:
  • 资助金额:
    $6.71万
  • 财政年份:
    2010
  • 负责人:
    MARK Edward BARDGETT
  • 依托单位:
海外基金